[go: up one dir, main page]

NO20072984L - Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment - Google Patents

Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment

Info

Publication number
NO20072984L
NO20072984L NO20072984A NO20072984A NO20072984L NO 20072984 L NO20072984 L NO 20072984L NO 20072984 A NO20072984 A NO 20072984A NO 20072984 A NO20072984 A NO 20072984A NO 20072984 L NO20072984 L NO 20072984L
Authority
NO
Norway
Prior art keywords
pyrido
pyrimidines
pharmaceutical compositions
medical treatment
compositions useful
Prior art date
Application number
NO20072984A
Other languages
English (en)
Inventor
Steven Cesar Alfons De Jonghe
Eduard Dolusic
Ling-Jie Gao
Piet Andre Maurits M Herdewijn
Wolfgang Eugen Pfleiderer
Original Assignee
4 Aza Ip Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4 Aza Ip Nv filed Critical 4 Aza Ip Nv
Publication of NO20072984L publication Critical patent/NO20072984L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen angår substituerte pyrido(3,2-d)pyrimidinderivater ifølge figur, deres farmasøytisk akseptable salter, N-oksider, solvater, prodrugs og enantiomerer med uventet ønskede farmasøytiske egenskaper og som spesielt er svært aktive immunosuppressive midler, og som sådan er nyttige i behandlingen av transplantatrejeksjon og/eller i behandlingen av visse inflammatoriske sykdommer. Disse derivatene er også anvendelige for å forhindre eller behandle kardiovaskulære forstyrrelser, forstyrrelser i sentralnervesystemet, TNF-a-relaterte forstyrrelser, virale sykdommer (inkludert hepatitt C), erektil dysfunksjon og celleproliferative forstyrrelser.
NO20072984A 2004-12-30 2007-06-12 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment NO20072984L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0428475.8A GB0428475D0 (en) 2004-12-30 2004-12-30 Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
US69389905P 2005-06-24 2005-06-24
PCT/EP2005/014187 WO2006069805A2 (en) 2004-12-30 2005-12-29 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment

Publications (1)

Publication Number Publication Date
NO20072984L true NO20072984L (no) 2007-09-10

Family

ID=34131009

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072984A NO20072984L (no) 2004-12-30 2007-06-12 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment

Country Status (10)

Country Link
US (1) US20080004285A1 (no)
EP (1) EP1831217A2 (no)
KR (1) KR20070102693A (no)
CN (1) CN101365699A (no)
AU (1) AU2005321492A1 (no)
CA (1) CA2594241A1 (no)
GB (1) GB0428475D0 (no)
NO (1) NO20072984L (no)
WO (1) WO2006069805A2 (no)
ZA (1) ZA200705281B (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO341055B1 (no) * 2005-11-22 2017-08-14 Kudos Pharm Ltd Pyridopyrimidinforbindelser og anvendelse derav,samt farmasøytisk preparat.

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899332A1 (en) 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
WO2008009079A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US9259426B2 (en) * 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
AU2007287430B2 (en) 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8143394B2 (en) 2006-12-26 2012-03-27 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8637531B2 (en) 2006-12-26 2014-01-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyridmidines useful for treating viral infections
US20090104160A1 (en) * 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
BRPI0912356A2 (pt) 2008-05-01 2015-10-06 Sirtris Pharmaceuticals Inc compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
MY172107A (en) 2008-06-20 2019-11-14 Astrazeneca Ab Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
US9100222B2 (en) * 2008-12-31 2015-08-04 Sybase, Inc. System and method for mobile user authentication
ES2570456T3 (es) 2009-02-12 2016-05-18 Merck Serono Sa 2-Morfolino-pirido[3,2-d]pirimidinas
CN101906085B (zh) * 2009-06-04 2013-12-11 天津药物研究院 治疗心脑血管疾病的化合物、组合物、制备方法及用途
WO2011053597A1 (en) * 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8440651B2 (en) * 2010-02-22 2013-05-14 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
JP5651239B2 (ja) * 2010-07-07 2015-01-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 複素環式抗ウイルス化合物
BR112013002375B1 (pt) 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto
CN102079813B (zh) * 2010-11-18 2012-05-30 浙江皇马科技股份有限公司 一种苯酚聚氧乙烯醚磷酸酯的制备方法
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CA2909310A1 (en) 2013-04-12 2014-10-16 Asana Biosciences, Llc Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
AU2016216673B2 (en) 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
GB201708856D0 (en) * 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms
CN108623582A (zh) * 2017-10-10 2018-10-09 河南省锐达医药科技有限公司 一类新型含取代基吡啶并嘧啶化合物的制备方法
CN108069963B (zh) * 2017-11-17 2020-01-14 清华大学 吡啶并嘧啶衍生物或其盐及其制法、药物组合物和用途
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN111171020A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
JP7749540B2 (ja) * 2019-09-05 2025-10-06 魯南製薬集団股▲分▼有限公司 Ｍａｇｌ阻害剤とその製造方法および使用
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用
KR102487604B1 (ko) * 2020-11-06 2023-01-12 에스케이케미칼 주식회사 히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물
CN113816924B (zh) * 2021-10-20 2023-11-03 苏州大学 一种基于炔基连接臂的苯并噻嗪酮衍生物及其制备方法与应用
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
CN117800969B (zh) * 2023-09-19 2024-11-29 武汉厚先生物医药有限公司 肿瘤坏死因子受体复合物抑制剂及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) * 1950-06-20 Substituted pteridines and method
US2924599A (en) * 1956-07-16 1960-02-09 Anchor Chemical Company Ltd Derivatives of 1:3:5-triazanaphthalene
US3952001A (en) * 1970-07-01 1976-04-20 The Boots Company Limited 1-Carbamoyl-1,2,4-triazoles
US3939268A (en) * 1971-04-10 1976-02-17 Boehringer Ingelheim Gmbh 2,4-Diamino substituted pyridol(3,2-d)pyrimidine as antithrombotic agents
US4492597A (en) * 1981-05-25 1985-01-08 Kureha Kagaku Kogyo Kabushiki Kaisha 1,5-Diphenyl derivative of 1,2,4-triazole-3-carboxamide and herbicide containing the same
US4460591A (en) * 1982-08-26 1984-07-17 Sri International 8,10-Dideazaminopterins
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
WO1990002745A1 (en) * 1988-09-16 1990-03-22 Sri International 8,10-dideazatetrahydrofolic acid derivatives
US5508281A (en) * 1991-04-08 1996-04-16 Duquesne University Of The Holy Ghost Derivatives of pyrido [2,3-d] and [3,2-d] pyrimidine and methods of using these derivatives
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents
US6962920B2 (en) * 1992-09-23 2005-11-08 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US5521190A (en) * 1993-05-27 1996-05-28 Fmc Corporation Insecticidal pterdines and 8-deazapteridines
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2281525A1 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6331547B1 (en) * 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6440991B1 (en) * 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
MXPA04005510A (es) * 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
PL371587A1 (en) * 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
WO2004055004A1 (en) * 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
PL1663244T3 (pl) * 2003-09-12 2008-01-31 4 Aza Ip Nv Pochodne pterydyny do leczenia chorób związanych z TNF-alfa
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO341055B1 (no) * 2005-11-22 2017-08-14 Kudos Pharm Ltd Pyridopyrimidinforbindelser og anvendelse derav,samt farmasøytisk preparat.

Also Published As

Publication number Publication date
GB0428475D0 (en) 2005-02-02
EP1831217A2 (en) 2007-09-12
ZA200705281B (en) 2008-07-30
WO2006069805A2 (en) 2006-07-06
CN101365699A (zh) 2009-02-11
WO2006069805A3 (en) 2007-01-25
CA2594241A1 (en) 2006-07-06
US20080004285A1 (en) 2008-01-03
KR20070102693A (ko) 2007-10-19
AU2005321492A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
NO20072984L (no) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
NO20074207L (no) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
DK1673092T3 (da) Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi
NO20082069L (no) 2-Amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-oner
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
MX2007007032A (es) Compuestos de aminopirimidina y metodos de uso.
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
TW200633980A (en) Pyridones useful as inhibitors of kinases
TW200734327A (en) Aminopyrimidines useful as kinase inhibitors
MX2009006700A (es) Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20075560L (no) Purin og imidazopyridin derivater for immunsuppresjon
MX2009003913A (es) Formas solidas que comprenden 4-[9-(tetrahidro-furano-3-il)-8-(2,4 ,6-trifluoro-fenilamino)-9h-purin-2-ilamino]-ciclohexan-1-ol, composiciones de las mismas, y su uso.
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
JO2755B1 (en) (Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection)
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
NO20063368L (no) Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
UA93522C2 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application